Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + durvalumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **carboplatin** and **cisplatin**, both platinum-based chemotherapeutic agents, **durvalumab**, an anti-PD-L1 monoclonal antibody used in immunotherapy, and **pemetrexed**, an antifolate chemotherapeutic agent. The combination is used to treat cancers like malignant pleural mesothelioma. Carboplatin and cisplatin work by inducing DNA damage in cancer cells, while durvalumab enhances the immune response against cancer cells by blocking the PD-L1/PD-1 pathway. Pemetrexed inhibits folate-dependent metabolic processes essential for cell replication.
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)CD274 (Programmed cell death protein 1 ligand 1)DNAGART (GAR transformylase)
Beyond the preview
Go deeper on carboplatin + cisplatin + durvalumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + durvalumab + pemetrexed.